.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Predict branded drug patent expiration
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Healthtrust
Express Scripts
Fish and Richardson
Citi
Teva
Cipla
Mallinckrodt
Baxter

Generated: July 20, 2017

DrugPatentWatch Database Preview

Posaconazole - Generic Drug Details

« Back to Dashboard

What are the generic sources for posaconazole and what is the scope of posaconazole patent protection?

Posaconazole
is the generic ingredient in one branded drug marketed by Schering and Merck Sharp Dohme, and is included in three NDAs. There are seven patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Posaconazole has one hundred and thirty-one patent family members in thirty-four countries.

There are twelve drug master file entries for posaconazole. One supplier is listed for this compound.

Summary for Generic Name: posaconazole

Tradenames:1
Patents:7
Applicants:2
NDAs:3
Drug Master File Entries: see list12
Suppliers / Packagers: see list1
Bulk Api Vendors: see list50
Clinical Trials: see list56
Patent Applications: see list49
Therapeutic Class:Antifungals
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:posaconazole at DailyMed

Pharmacology for Ingredient: posaconazole

Ingredient-typeAzoles
Drug ClassAzole Antifungal
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck Sharp Dohme
NOXAFIL
posaconazole
TABLET, DELAYED RELEASE;ORAL205053-001Nov 25, 2013RXYesYes5,661,151► SubscribeYY ► Subscribe
Merck Sharp Dohme
NOXAFIL
posaconazole
SOLUTION;IV (INFUSION)205596-001Mar 13, 2014RXYesYes8,410,077► SubscribeY ► Subscribe
Merck Sharp Dohme
NOXAFIL
posaconazole
SOLUTION;IV (INFUSION)205596-001Mar 13, 2014RXYesYes9,358,297► SubscribeY ► Subscribe
Schering
NOXAFIL
posaconazole
SUSPENSION;ORAL022003-001Sep 15, 2006RXYesYes8,263,600► SubscribeY ► Subscribe
Merck Sharp Dohme
NOXAFIL
posaconazole
SOLUTION;IV (INFUSION)205596-001Mar 13, 2014RXYesYes9,493,582► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: posaconazole

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck Sharp Dohme
NOXAFIL
posaconazole
SOLUTION;IV (INFUSION)205596-001Mar 13, 20145,703,079► Subscribe
Schering
NOXAFIL
posaconazole
SUSPENSION;ORAL022003-001Sep 15, 20065,703,079► Subscribe
Merck Sharp Dohme
NOXAFIL
posaconazole
TABLET, DELAYED RELEASE;ORAL205053-001Nov 25, 20135,703,079► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: posaconazole

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,635,773Sulfoalkyl ether cyclodextrin compositions► Subscribe
5,710,154 Tetrahydrofuran antifungals► Subscribe
5,714,490 Tetrahydrofuran antifungals► Subscribe
6,713,481 Crystalline antifungal polymorph► Subscribe
5,703,079 Tetrahydrofuran antifungals► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: posaconazole

Country Document Number Estimated Expiration
South Korea20150004797► Subscribe
Spain2199291► Subscribe
South Korea0179990► Subscribe
Japan2012072160► Subscribe
Norway316173► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: POSACONAZOLE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C003/2006Ireland► SubscribeSPC003/2006: 20061023, EXPIRES: 20191219
C/GB06/007United Kingdom► SubscribePRODUCT NAME: POSACONAZOLE, OPTIONALLY IN THE FORM OF AN ESTER OR PHARMACEUTICALLY ACCEPTABLE SALT.; REGISTERED: UK EU/1/05/320/001 20051025; UK EU/1/05/321/001 20051025
0736030/01Switzerland► SubscribeFORMER OWNER: SCHERING CORPORATION, US
216Luxembourg► Subscribe91216, EXPIRES: 20191220
C0009France► SubscribePRODUCT NAME: POSACONAZOLE; REGISTRATION NO/DATE: EU/1/05/320/001 20051025
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Covington
Dow
Daiichi Sankyo
Chubb
Merck
Cantor Fitzgerald
AstraZeneca
Boehringer Ingelheim
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot